Luis Malavé Named Glucotrack Board Chairman

Glucotrack Inc.’s Board of Directors has elected Luis Malavé as chairman.
 
“I can think of no better person to lead our board during this time for Glucotrack,” board member Andrew Sycoff said. “With a deep commitment to the mission and values of the organization, Luis will be an invaluable strategic leader for the continued growth of the company.”
 
Malavé has more than 30 years of medtech industry leadership experience, primarily in diabetes management, spanning all company stages from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and U.S. Food and Drug Administration regulatory strategy. 

“We are very fortunate to have Luis’ leadership on the Board of Directors. He has been an incredible champion of Glucotrack’s vision throughout his entire tenure on our board,” Glucotrack President/CEO Paul V. Goode, Ph.D., stated. “His experience across the diabetes market provides him with valuable insights that will benefit us as we progress the development of our implantable continuous blood glucose monitor (CBGM) for people living with diabetes.”
 
Malavé currently is president of EOFLOW Co. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. Before that, Malavé was president and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., joining as its senior vice president of Research, Development and Engineering in the first year and as chief operating officer as Insulet grew to a multi-billion dollar public company. He also held various senior management positions at MiniMed, fueling its innovation and growth to eventual acquisition by Medtronic. Malavé has served on Glucotrack’s board since 2021.

Malavé earned his bachelor’s degree in mathematics and computer science from the University of Minnesota, a master’s degree in software engineering from the University of St. Thomas, and an MBA from the University of Maryland.
 
“I am honored to take on this important role,” Malavé said. “Glucotrack has a technology that will address unmet needs and expand patient choice in the diabetes market. I look forward to working with the board and the leadership team to further strengthen the company’s foundation, to build out its operational capacity, to advance the clinical program, and to continue to create value for all our stakeholders and patients with diabetes.” 
 
GlucoTrack Inc. designs, develops, and commercializes technologies for people with diabetes. The company is currently developing a long-term implantable continuous glucose monitoring system.